Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESALIT
2024-513955-34-00Phase 2Authorised
- Sponsor
- Centre Hospitalier Universitaire Dijon Bourgogne
- Start
- Dec 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of lithium carbonate in TBR1-related neurodevelopmental disorder (IDDAS), intellectual disability (ID) and Autism Spectrum Disorder (ASD) (2 arms), sponsored by Centre Hospitalier Universitaire Dijon Bourgogne. Planned start Dec 2024; status: authorised.
02
Drugs
lithium carbonate
03
Conditions
TBR1-related neurodevelopmental disorder (IDDAS)intellectual disability (ID)Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on 2024-513955-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513955-34-00.